eyeFlow, Inc. Obtains Colombia Approval for its Pilot Clinical Study

Feb 14

Bogota, Colombia. On February 14, 2024, INVIMA, Colombia's regulatory agency, approved a pilot study by eyeFlow, Inc. at one research center in Barranquilla. This pilot clinical trial aims to recruit 60 subjects in Colombia and will last approximately 18 months. eyeFlow, Inc. is an emerging eye care company from Mission Viejo, California, developing a revolutionary glaucoma treatment. Glaucoma is a group of eye conditions that can result in vision loss and blindness.

Source: INVIMA's Medical Device Committee, February 14, 2024 meeti ng minutes.

eyeFlow IncColombiaClinical research in Latin AmericaMedical device CRO in Latin AmericaMedical device clinical trialsMedtech clinical trialsEarly feasibility studyEarly-feasibility clinical trialsFirst-in-human clinical trialsFirst-in-human study

Julio G. Martinez-Clark http://www.juliomartinezclark.com/

eyeFlow, Inc. Obtains Colombia Approval for its Pilot Clinical Study

How Medtech Companies are Unlocking the Potential of Latin America in Clinical Research

i-Lumen Scientific, Inc. Obtains Colombia Approval for its i-Sight 2 Clinical Study